FuRST 2.0 Cognitive Pre-Testing

Status Completed

Clinical Trial Summary

The FuRST 2.0 scale is being developed as a Patient Reported Outcome (PRO) with information coming directly from the Huntington's Disease Gene Expansion Carrier (HDGEC) and companion through self-report. The purpose of this study is to identify real or potential comprehension or usage problems with questionnaire items or response options. Through a process of structured cognitive de-briefing with HDGEC participants and companions, independently, followed by qualitative analysis, the final phrasing of the individual items and response options for the scale will be generated. Depending on the results of the first round of cognitive pre-testing, additional rounds of cognitive pre-testing may be required.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02881931
Study type	Observational
Source	CHDI Foundation, Inc.
Contact
Status	Completed
Phase	N/A
Start date	February 28, 2017
Completion date	July 28, 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04120493` - Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease	Phase 1/Phase 2
Completed	`NCT02956148` - Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers	Early Phase 1
Terminated	`NCT02494778` - A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease	Phase 2
Completed	`NCT02216474` - Brain Stimulation in Movement Disorders	N/A
Completed	`NCT02208934` - Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers	Phase 1
Completed	`NCT02197130` - Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease	Phase 2
Completed	`NCT01806896` - Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease	Phase 2
Completed	`NCT01502046` - Neuroprotection by Cannabinoids in Huntington's Disease	Phase 2
Terminated	`NCT00712426` - Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)	Phase 3
Completed	`NCT00670709` - Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease
Completed	`NCT00029874` - Minocycline in Patients With Huntington's Disease	Phase 1/Phase 2
Terminated	`NCT02231580` - Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients	Phase 2
Completed	`NCT02215616` - A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod	Phase 2
Not yet recruiting	`NCT02551705` - Functional Imaging of Social Cognition in Premanifest Huntington's Disease	N/A
Active, not recruiting	`NCT02101957` - Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)	Phase 2/Phase 3
Completed	`NCT00990613` - A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin	Phase 1
Completed	`NCT01521832` - Escalating Dose Study in Healthy Volunteers With SEN0014196	Phase 1
Completed	`NCT00975481` - A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users	Phase 1
Completed	`NCT00387270` - Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease	Phase 1/Phase 2
Completed	`NCT00095355` - Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington's Disease	Phase 2